HYPER-CVAD regimen: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|doxorubicin (Adriamycin)]], and [[dexamethasone]] used to treat some forms of [[ | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|doxorubicin (Adriamycin)]], and [[dexamethasone]] used to treat some forms of [[Burkitt's lymphoma]], [[diffuse large B-cell lymphoma]], and [[multiple myeloma]].<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref><ref name="pmid24117234">{{cite journal| author=Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S et al.| title=Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. | journal=Br J Haematol | year= 2013 | volume= 163 | issue= 5 | pages= 611-20 | pmid=24117234 | doi=10.1111/bjh.12585 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24117234 }} </ref><ref name="pmid16502413">{{cite journal| author=Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al.| title=Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. | journal=Cancer | year= 2006 | volume= 106 | issue= 7 | pages= 1569-80 | pmid=16502413 | doi=10.1002/cncr.21776 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16502413 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 13: | Line 13: | ||
{{chemo|V|Vincristine (Oncovin)}} | {{chemo|V|Vincristine (Oncovin)}} | ||
{{chemo|A|Doxorubicin (Adriamycin | {{chemo|A|Doxorubicin (Adriamycin)}} | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
| Line 19: | Line 19: | ||
==Indications== | ==Indications== | ||
* [[Multiple myeloma]].<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref> | * [[Multiple myeloma]].<ref name="pmid22058209">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.| title=Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. | journal=Haematologica | year= 2012 | volume= 97 | issue= 3 | pages= 442-50 | pmid=22058209 | doi=10.3324/haematol.2011.043372 | pmc=PMC3291601 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058209 }} </ref> | ||
* [[Diffuse large B-cell lymphoma]]<ref name="pmid24117234">{{cite journal| author=Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S et al.| title=Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. | journal=Br J Haematol | year= 2013 | volume= 163 | issue= 5 | pages= 611-20 | pmid=24117234 | doi=10.1111/bjh.12585 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24117234 }} </ref> | |||
* [[Burkitt's lymphoma]]<ref name="pmid16502413">{{cite journal| author=Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al.| title=Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. | journal=Cancer | year= 2006 | volume= 106 | issue= 7 | pages= 1569-80 | pmid=16502413 | doi=10.1002/cncr.21776 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16502413 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 17:00, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
HYPER-CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of Burkitt's lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.[1][2][3]
Regimen
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.
- ↑ 2.0 2.1 Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S; et al. (2013). "Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma". Br J Haematol. 163 (5): 611–20. doi:10.1111/bjh.12585. PMID 24117234.
- ↑ 3.0 3.1 Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G; et al. (2006). "Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia". Cancer. 106 (7): 1569–80. doi:10.1002/cncr.21776. PMID 16502413.